In Burkitt’s lymphoma, EBV-mediated activation of the mTOR pathway correlated with fewer mutations in developed cancers, which the authors suggested was due to the presence of activated mTOR that bypasses the need for oncogenic mutations [56]. Here, MTOR is linked to Burkitt lymphoma.